Depomed Inc (DEPO)

20.20
NASDAQ : Health Care
Prev Close 20.05
Day Low/High 20.00 / 20.49
52 Wk Low/High 12.25 / 27.02
Avg Volume 1.87M
Exchange NASDAQ
Shares Outstanding 61.58M
Market Cap 1.23B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

January 2017 Options Now Available For Depomed (DEPO)

January 2017 Options Now Available For Depomed (DEPO)

Investors in Depomed Inc saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.

Depomed Announces New CAMBIA® Formulation

Depomed Announces New CAMBIA® Formulation

- Formulation Removes Sweetener Aspartame -

Starboard DepoMed Director Deal Bolsters Sale Prospects

Starboard DepoMed Director Deal Bolsters Sale Prospects

The pain medication maker struck a deal with the fund managed by insurgent Jeff Smith to install a minority-slate of three dissident directors onto its board.

Drug Win for Depomed Could Be Hurdle for Starboard

Drug Win for Depomed Could Be Hurdle for Starboard

Increased chance for company's sale presents activist campaign with a steeper climb.

Depomed (DEPO) Closed Higher on Favorable Patent Ruling

Depomed (DEPO) Closed Higher on Favorable Patent Ruling

A New Jersey District Court has ruled in favor of Depomed's (DEPO) patents for its Nucynta drug franchise.

First Week of November 18th Options Trading For Depomed (DEPO)

First Week of November 18th Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Arbor and Purdue Seen as Likely Bidders for DepoMed

Arbor and Purdue Seen as Likely Bidders for DepoMed

The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.

Starboard Delivers Special Meeting Request To Depomed And Issues Letter To Depomed Shareholders

Starboard Delivers Special Meeting Request To Depomed And Issues Letter To Depomed Shareholders

Sets November 15, 2016 as the Date for the Special Meeting and Believes Depomed Has Notified Broadridge of a September 27, 2016 Record Date

Depomed Receives Request To Call Special Meeting Of Shareholders

Depomed Receives Request To Call Special Meeting Of Shareholders

Depomed Shareholders Not Required to Take Action at This Time

Stocks End Volatile Week With Fed Meeting in Focus

Stocks End Volatile Week With Fed Meeting in Focus

Wall Street closed out a volatile week with slight losses as the Federal Reserve stays in focus.

Stocks Slide as Oil Settles Barely Above $43

Stocks Slide as Oil Settles Barely Above $43

Stocks hold lower on Friday as crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.

Stocks Hold Lower as Fed Meeting Looms, Crude Slides

Stocks Hold Lower as Fed Meeting Looms, Crude Slides

Stocks fall on Friday as Wall Street eagerly awaits next week's meeting of the Federal Reserve.

Depomed (DEPO) Stock Soars Amid Sale Speculation

Depomed (DEPO) Stock Soars Amid Sale Speculation

Depomed (DEPO) stock was spiking on Friday morning as the company is reportedly preparing to explore a sale.

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

The buyer's CEO said it will look at both large acquisitions and Phase 2 and pre-approved assets in the wake of the $800 million purchase of the maker of Procysbi.

Perrigo Shares Spike After Starboard's Smith Urges Asset Sales

Perrigo Shares Spike After Starboard's Smith Urges Asset Sales

Perrigo is the second drug company that the activist has targeted in recent months after it rejected an unsolicited bid.

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon says the $800 million offer will bolster its rare disease business and its operations outside the U.S..

4 Breakout Stocks to Watch

4 Breakout Stocks to Watch

These four stocks are looking strong technically, either breaking out or approaching breakout levels.

Short Interest Declines 12.4% For DEPO

Short Interest Declines 12.4% For DEPO

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 1,640,757 share decrease in total short interest for Depomed Inc , to 11,618,047, a decrease of 12.37% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.